Theoretically, TBK1 may induce the resistance of HCC cells to molecularly-targeted drugs, and our results show that patients with a high TBK1 expression in HCC tissues have a poor prognosis after receiving sorafenib treatment. This evidence concerns the gene TBK1 and hepatocellular carcinoma.